

# Burcin zdirik

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6647424/burcin-ozdirik-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

63  
citations

4  
h-index

7  
g-index

17  
ext. papers

131  
ext. citations

4.6  
avg, IF

2.52  
L-index

#	Paper	IF	Citations
14	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 217-236	5.6	4
13	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 14, 20	1.6	1
12	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 652172	8.4	7
11	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review. <i>Medicine (United States)</i> , <b>2021</b> , 100, e26377	1.8	2
10	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
9	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
8	PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. <i>Medicine (United States)</i> , <b>2021</b> , 100, e23835	1.8	3
7	A case report of an excellent response to interferon- $\beta$ in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , <b>2020</b> , 99, e20820	1.8	0
6	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
5	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , <b>2020</b> , 7, HEP20	4	16
4	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244504	3.7	2
3	In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
2	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
1	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10